Vermillion gets new CEO
This article was originally published in Clinica
Women's health diagnostics specialist Vermillion has appointed Thomas McLain president and CEO, replacing Bruce Huebner, who was heading up the company on an interim basis. Mr Huebner will remain a director of the firm and help with the transition. The appointment comes almost a year after former CEO Gail Page announced she was leaving Vermillion after eight years at the helm (www.clinica.co.uk, 22 May 2012). Mr McLain previously served as CEO and CFO of early-stage diagnostic company Claro Scientific; before this, he held various senior management positions, including CEO, at Nabi Biopharmaceuticals (now Biota Pharmaceuticals), a biotechnology company addressing immune system conditions; and has also worked for eye care giant Bausch + Lomb.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.